Roche Holding AG (RHHBF)
| Previous close | 426.86 |
| Open | 422.49 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 421.71 - 422.49 |
| 52-week range | 320.00 - 473.65 |
| Volume | 17 |
| Avg. volume | 132 |
| Market cap | 333.354B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 23.79 |
| EPS (TTM) | 17.73 |
| Earnings date | N/A |
| Forward dividend & yield | 9.78 (2.29%) |
| Ex-dividend date | 18 Mar 2021 |
| 1y target est | N/A |
- GlobeNewswire
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. This is the first time that research scientists can conduct oncology research with Foundation Medicine’s comprehensive genomic profiling in their own laboratories to gain meaningful genomic insights and deepen their understanding of cancer biology. This kit is an importan
- Motley Fool
Why Atea Pharmaceuticals Stock Got Crushed This Week
Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).
- GlobeNewswire
FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per yearNeovascular AMD impacts approximately 20 million people worldwide and is a leading cause of blindness in people over the age of 6
